Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Henning Demay maintains a patent portfolio in the Biotechnology & Pharmaceuticals technology area. The portfolio currently shows 1 pending office action. This activity involves 1 distinct examiner and is situated within a distinct art unit, representing a very specific focus for the current examination process.
The busiest examiner for the portfolio is SINGH, SATYENDRA K, who is currently managing the 1 pending office action. This single action accounts for all active matters reported for the company. The concentration of the current workload under one examiner suggests that the prosecution is focused on a specific pharmaceutical development.
Practitioners should recognize that this individualized structure allows for a direct and consistent technical exchange. Success in this matter requires a thorough understanding of the examiner's perspective on biotechnological patentability, as there are no other active matters to provide broader context.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Double-patenting + other | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| SINGH, SATYENDRA K | 1 | 61.5% | +67.9% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17916193 | NANOPARTICLE-LOADED SILICIFIED CELLS, METHODS OF MAKING, AND METHODS OF USE | SINGH, SATYENDRA K | — |
| Art Unit | Apps |
|---|---|
| 1657 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 17916193 | NANOPARTICLE-LOADED SILICIFIED CELLS, METHODS OF MAKING, AND METHODS OF USE | SINGH, SATYENDRA K | 1657 | §103DP | Final Rejection | — | Pending | Sep 30, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialHenning Demay has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Satyendra K Singh has the most, with 1 of Henning Demay's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
